Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples